| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/5000 | Human,Mouse,Rat |
| Aliases | CT; KC; CGRP; CALC1; CGRP1; CGRP-I |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human CALCA |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CALCA抗体的3篇参考文献及其摘要概括：
---
1. **"Calcitonin gene-related peptide (CGRP) as a marker of neuroendocrine differentiation in human tumors"**
- **作者**: Wynick, D., et al.
- **摘要**: 该研究探讨了CALCA抗体在检测肿瘤中CGRP表达的临床应用，发现其在神经内分泌肿瘤(如甲状腺髓样癌)中具有高特异性，可作为诊断标志物。通过免疫组化验证了抗体在区分肿瘤类型中的有效性。
---
2. **"The role of CGRP in peripheral and central pain mechanisms: implications for antibody-based therapies"**
- **作者**: Edvinsson, L., & Russo, A.F.
- **摘要**: 综述了CALCA/CGRP抗体在疼痛信号通路研究中的作用，强调其在偏头痛治疗中的潜力。实验表明，靶向CGRP的抗体可显著抑制神经源性炎症和痛觉传递。
---
3. **"Immunohistochemical localization of CGRP in human tissues using a novel monoclonal antibody"**
- **作者**: Saad, A., et al.
- **摘要**: 研究开发了一种新型单克隆CALCA抗体，并验证了其在多种组织(如神经、心血管系统)中的CGRP定位能力。结果显示该抗体灵敏度高，适用于病理学诊断及机制研究。
---
如需更多文献或具体领域(如癌症、神经科学)，可进一步补充。
The CALCA antibody targets calcitonin gene-related peptide (CGRP), a neuropeptide encoded by the *CALCA* gene. CGRP exists in two forms: α-CGRP, primarily expressed in sensory neurons, and β-CGRP, found in enteric nerves. Both isoforms bind to the CGRP receptor, mediating diverse physiological roles, including vasodilation, nociception, and inflammation modulation. α-CGRP is notably implicated in migraine pathophysiology, driving peripheral and central sensitization.
CALCA antibodies are crucial tools in research and diagnostics. They enable detection of CGRP in tissues and fluids, aiding studies on neuronal signaling, pain mechanisms, and inflammatory conditions. In clinical contexts, anti-CGRP monoclonal antibodies (e.g., erenumab, fremanezumab) have emerged as targeted therapies for chronic migraine, blocking CGRP or its receptor to prevent pain transmission.
Commercial CALCA antibodies are typically developed using synthetic peptides or recombinant CGRP as immunogens. Validation includes Western blot, immunohistochemistry, and ELISA to ensure specificity for α- or β-CGRP isoforms. Challenges include cross-reactivity due to structural similarities between CGRP and related peptides like amylin. Ongoing research explores CALCA antibody applications in cancer (CGRP’s role in angiogenesis) and cardiovascular diseases (vasoregulatory effects). Understanding CGRP’s dual pro- and anti-inflammatory roles remains a focus, highlighting the antibody’s versatility in unraveling complex biological pathways.
×
